Suppr超能文献

药物涂层球囊血管成形术治疗股浅动脉闭塞性疾病自膨式覆膜支架置入后边缘狭窄

Drug-coated balloon angioplasty for the treatment of edge stenosis after self-expanding covered stent placement for superficial femoral artery occlusive disease.

机构信息

Department of Surgery, 1322Rijnstate Hospital, Arnhem, the Netherlands.

Department of Surgery, Antonius Hospital, Sneek, the Netherlands.

出版信息

Vascular. 2021 Feb;29(1):108-115. doi: 10.1177/1708538120943319. Epub 2020 Jul 23.

Abstract

BACKGROUND

Edge stenoses are the predominant limitation of self-expanding covered stent treatment of superficial femoral artery (SFA) occlusive disease, necessitating reinterventions. Angioplasty of an edge stenosis is associated with a high recurrence rate. Drug-coated balloon (DCB) treatment of edge stenoses might improve outcomes by decreasing the incidence of restenosis.

PURPOSE

The aim of this study was to evaluate the outcomes of using a DCB for the treatment of edge stenoses after self-expanding covered stent placement for SFA occlusive disease.

METHOD

We performed a retrospective analysis of patients treated with a DCB for edge stenoses after self-expanding covered stent placement. The primary endpoint was primary patency at one year. The secondary endpoints included procedure-related complications, secondary patency, and freedom from target lesion revascularization (TLR).

RESULTS

A total of 21 patients with 28 edge stenoses were included. The time from primary treatment to treatment of the edge stenosis was 19 months (interquartile range (IQR) 8; 52 months). Primary patency and assisted primary patency at one year were 66.7% with a secondary patency of 90.9%. Freedom from TLR was 86.1%, and freedom from clinically driven TLR was 89.4%. Four patients presented with a hemodynamically significant restenosis, and three of those patients had an occlusion. Median time to failure was six months (IQR 3.5; 7.0 months), and median time to occlusion was four months (IQR 3.0; 6.0 months).

CONCLUSION

The treatment of edge stenoses using a DCB is associated with a safe one-year outcome; however, this has to be confirmed in larger prospective studies. The continuous surveillance of patients is indicated.

摘要

背景

边缘狭窄是导致股浅动脉(SFA)闭塞性疾病自膨式覆膜支架治疗的主要限制因素,需要再次介入治疗。边缘狭窄处的血管成形术与高复发率相关。药物涂层球囊(DCB)治疗边缘狭窄可能通过降低再狭窄发生率来改善治疗效果。

目的

本研究旨在评估自膨式覆膜支架治疗股浅动脉闭塞性疾病后,使用 DCB 治疗边缘狭窄的效果。

方法

我们对接受 DCB 治疗自膨式覆膜支架治疗后边缘狭窄的患者进行了回顾性分析。主要终点为一年时的初始通畅率。次要终点包括与手术相关的并发症、二级通畅率和免于靶病变血运重建(TLR)。

结果

共纳入 21 例 28 处边缘狭窄患者。从初次治疗到治疗边缘狭窄的时间为 19 个月(四分位间距(IQR)8;52 个月)。一年时的初始通畅率和辅助初始通畅率分别为 66.7%和 90.9%。免于 TLR 的比例为 86.1%,免于临床驱动的 TLR 的比例为 89.4%。4 例患者出现血流动力学意义上的再狭窄,其中 3 例发生闭塞。失败的中位时间为 6 个月(IQR 3.5;7.0 个月),闭塞的中位时间为 4 个月(IQR 3.0;6.0 个月)。

结论

使用 DCB 治疗边缘狭窄的安全性在一年时得到了验证,但这需要在更大的前瞻性研究中得到证实。建议对患者进行持续监测。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验